Heart failure with preserved ejection fraction (HFpEF) poses a significant challenge because of its heterogeneous nature and the scarcity of therapies that meaningfully alter its course. The SUMMIT study evaluated the impact of tirzepatide on symptoms and mortality in people with HFpEF and obesity.

Guests: Jennifer N. Clements, Pharm.D., FCCP, FADCES, BCPS, BCACP, BC-ADM, CDCES and Dawn C. Fuke, Pharm.D., BCPS, BCACP

Music by Good Talk